Sanofi: positive results in atopic dermatitis
(CercleFinance.com) - Sanofi has presented positive results for a pivotal clinical phase III trial on dupixent (dupilumab) as a monotherapy in moderate-to-severe atopic dermatitis, at the 27th Congress of the European Academy of dermatology and venerology (EAVD) in Paris.
The product has significantly improved signs and symptoms, as well as certain quality-of-life measures, in inadequately controlled adolescents controlled by topical treatments or with whom these treatments were not recommended.
The results of this clinical trial will be used as a basis for applications for regulatory approval of dupixent in patients aged 12 to 17 years old. There is currently no systemic biological treatment approved for this category of patients.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The product has significantly improved signs and symptoms, as well as certain quality-of-life measures, in inadequately controlled adolescents controlled by topical treatments or with whom these treatments were not recommended.
The results of this clinical trial will be used as a basis for applications for regulatory approval of dupixent in patients aged 12 to 17 years old. There is currently no systemic biological treatment approved for this category of patients.
Copyright (c) 2018 CercleFinance.com. All rights reserved.